BRCA1 (Breast cancer 1, early onset)

P=N/A, N=63, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

By adopting a structured, evidence-based approach to genetic testing and personalised care, Egypt can enhance treatment outcomes, reduce healthcare expenditures and align with global trends in precision oncology. The integration of genetic testing into routine oncology care not only supports clinical decision-making but also represents a strategic investment in the long-term sustainability and efficiency of Egypt's healthcare system.

These variants are segregated with disease in the respective families and are predicted to affect protein function. Our findings highlight the importance of germline genomic analysis in characterizing hereditary cancer predisposition in underrepresented populations and provide preliminary data for future risk assessment and genetic counseling strategies in Palestine.

Large-panel NGS testing in cancer patients is transforming family-based risk management by enabling the identification of homologous recombination repair (HRR) genes (including ATM) beyond BRCA1/2. Cascade testing via comprehensive NGS provides tangible clinical benefits by detecting malignancies early in clinically silent carriers.

Molecular docking analyses suggested potential interactions with several signaling proteins, including Src, MAPK14, GSK3β, PDGFRA, and VEGFR2. Collectively, these findings identify compounds 26 and 27 as biologically active purine analogues with promising anti-HGSOC activity and support further evaluation in advanced preclinical models.

All of these observations point towards the necessity to combine mechanistic knowledge with clinical innovation to enhance the selection of patients and the sustainability of therapy. The development of biomarker-mediated and combination approaches will play a vital part in increasing the efficacy of PARP inhibitors and the results achieved among patients with breast cancer.

Our findings suggest an unexpected major role for TP53 and PALB2 as key PCa susceptibility genes, reinforce the role of BRCA2 and ATM, and question the role of BRCA1. Genetic testing may be most informative when focused on younger patients with non-low-risk disease and relevant FH.

In addition, SGO2 compromised the cisplatin (CDDP) sensitivity of LUAD in vitro and in vivo...Silencing SGO2 with OA improved LUAD chemo sensitivity. Our work highlights the potential of SGO2 as a target for therapeutic intervention and OA as a food-bioactive compound for LUAD treatment.

Perceived risk was intertwined with cancer worry, and individuals made decisions regarding RRSO based on factors such as perceived risk, control, family planning, hormonal impacts, and recovery. Importantly, healthcare providers exerted both direct and indirect influences on the decision-making process.

In this retrospective cross-sectional study, cascade testing was underused, especially among specific demographic groups, with clinical and cultural factors appearing to play a larger role than financial barriers. These findings may guide efforts to address barriers preventing wider uptake of cascade testing and improve cancer prevention efforts, particularly among racial and ethnic minority groups.

Finally, we summarize current challenges-including limited accessibility, resistance mechanisms, and toxicities-and outline future directions, such as novel biomarkers, liquid biopsy for real-time resistance monitoring, and innovative adaptive trial designs. This review highlights the evolution of DDR-targeted therapy in pancreatic cancer toward personalized, combination-based precision medicine.

Secondly, it critically assesses advanced nanomedicine strategies such as PLGA-PEG nanoparticles, lipid-polymer hybrid nanoparticles, and biomimetic RBC membrane-camouflaged carriers-designed to address pharmacokinetic limitations. Thirdly, and most importantly, it proposes a biomarker-driven framework, centered on BRCA1 methylation and HIF-1α, along with a three-phase translational roadmap to advance salidroside into a precision nanomedicine for TNBC.